tiprankstipranks
Company Announcements

Medicus Pharma Advances Non-Invasive Skin Cancer Treatment in UAE

Story Highlights
Medicus Pharma Advances Non-Invasive Skin Cancer Treatment in UAE

The latest update is out from Medicus Pharma Ltd ( (MDCX) ).

Medicus Pharma Ltd has submitted a Phase 2 clinical design to the UAE Department of Health for a study aimed at non-invasively treating basal cell carcinoma of the skin. The study will involve 36 participants across four clinical sites in the UAE and will evaluate the efficacy of two dose levels of D-MNA. The company’s previous Phase 1 study demonstrated safety and tolerability, and the ongoing Phase 2 study in the United States is progressing well, with plans to seek FDA fast-track approval.

More about Medicus Pharma Ltd

Medicus Pharma Ltd is a pharmaceutical company operating in the healthcare industry, focusing on developing non-invasive treatments for skin conditions such as basal cell carcinoma (BCC). The company is involved in clinical research and development, with a market focus on innovative dermatological therapies.

Average Trading Volume: 1,347

Technical Sentiment Consensus Rating: Strong Sell

Current Market Cap: C$67.84M

Learn more about MDCX stock on TipRanks’ Stock Analysis page.

Questions or Comments about the article? Write to editor@tipranks.com

Questions or Comments about the article? Write to editor@tipranks.com
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App